Cargando…
Infliximab: 12 years of experience
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Control of inflammation and rapid suppression of cytokines are important in treating these diseas...
Autores principales: | Smolen, Josef S, Emery, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123963/ https://www.ncbi.nlm.nih.gov/pubmed/21624181 http://dx.doi.org/10.1186/1478-6354-13-S1-S2 |
Ejemplares similares
-
Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019) -
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
por: Han, Chenglong, et al.
Publicado: (2007) -
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019) -
Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008) -
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)